Cancer Treatment Centers Of America Improves Patient’s Care Through Collaboration

Cancer Treatment Centers of America (CTCA)has once again thought outside the box in relation to cancer care. A new collaboration was announced between Allscripts, NantHealth, and the Cancer Treatment Centers of America that would cut down on the guesswork in choosing the proper treatment pathway for a patient’s cancer diagnoses. The Clinical Pathways program is composed of Allscripts’ Sunrise, electric health record, and NantHealth’s “eviti“, a comprehensive support program, listing all data complied regarding any type of cancer and cross referencing this information with all possible treatment plans.

This program allows a more efficient exchange of information, while not interfering with the doctor’s work flow. Eviti also allows the patient greater access of information surrounding the type and stage of their cancer diagnosis, help them choose the best plan of care for their situation. The Eviti portion of Clinical Pathways has been developed compiling the most comprehensive and up to date treatments, medical research, and pharmaceutical information available. Eviti is kept updated by a team of oncologists, oncology nurses, a board of certified oncology experts, and technical experts.

This collaboration is the latest step in offering the best in cancer care at Cancer Treatment Centers of America. Headquartered in Boca Raton, Florida with buildings in Philadelphia, Atlanta, Chicago, Phoenix, and Tulsa, Cancer Treatment Centers of Americahas been consistently ranked as one of the top hospitals for a high standard of patient care several years running.

CTCA believes in treating the patient as a whole (mind, body, and soul) offering treatments to support the patient while they are going through cancer treatment. Cancer Treatment Centers of America even offers aftercare therapy for when a patient has finished their course of treatments. CTCA specializes in: precision cancer treatment, surgery, radiation, chemotherapy, immunotherapy, and genomic testing. To read more about the partnership, please click here.

Leave a Reply

Your email address will not be published. Required fields are marked *